Development and Validation of a New LC-MS/MS Method for the Assay of Plasmatic Peripheral Short- and Medium-Chain Fatty Acids for Metabolomics Applications

TL;DR

This paper introduces a new LC-MS/MS method to accurately measure short- and medium-chain fatty acids in human blood for metabolomics studies.

Contribution

A novel and validated LC-MS/MS method for quantifying plasmatic SCFAs and MCFAs in human samples is developed.

Findings

The method was validated for selectivity, sensitivity, accuracy, and precision according to current guidelines.

The method was successfully tested in an in vivo study to quantify peripheral SCFAs as biomarkers for gut–brain axis disruption.

The developed method includes sample cleanup, preparation, and derivatization for accurate quantification.

Abstract

Background: Short-chain fatty acids (SCFAs) and medium-chain fatty acids (MCFAs) are human metabolites which are involved in various biochemical processes and can offer valuable insights and information on various pathological and metabolic issues of patients. Accurate, precise, high-performance bioanalytical methods are important tools in both research and diagnostics of many pathologies, with LC-MS being the most frequently used methodology in modern metabolomics studies. Methods: The current paper describes a complete LC-MS/MS methodology for the accurate quantification of total plasmatic SCFA concentrations in humans using high-resolution QTOF mass spectrometric detection, including sample cleanup, preparation, and derivatization. Results and Conclusions: The method was validated with regard to all relevant parameters (selectivity, sensitivity, accuracy, precision, linearity, recovery, carryover, and reproducibility of sample preparation) according to the current applicable guidelines and tested in an in vivo study to quantify peripheral SCFAs in human patients as biomarkers for gut–brain axis disruption.

Figures